# Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

> **NCT05271292** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Advanced Solid Malignant Tumor

## Interventions

- **DRUG:** Chiauranib

## Key facts

- **NCT ID:** NCT05271292
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2025-03
- **Final completion:** 2025-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271292, "Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05271292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*